Trial to compare two Genentech drugs

02/22/2007 | Wall Street Journal, The

Genentech is urging doctors to use its Lucentis drug to treat age-related macular degeneration, but some doctors choose to use Genentech's cancer drug Avastin instead, even though Avastin is not FDA-approved to treat eye problems. The federal government is stepping in by conducting an NIH-funded comparison trial of the two biotech drugs. BIO argues that the NIH should study cutting-edge science rather than spend money to compare two approved drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX